China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

On February 25, 2022, GUANGZHOU WONDFO BIOTECH CO.,LTD signed a cooperation agreement with Merck, the world's leading technology company.

The COVID-19 pandemic has revealed a frightening reality; the course of infection with this disease is highly variable. Some young patients have died from the virus, whereas some elderly people have survived without experiencing respiratory symptoms at all. Researchers are left wondering: why?

Castle Biosciences reported after the close of the market on Monday that its fourth quarter revenues increased 45 percent year over year, while full-year revenues climbed 50 percent.

Chinese biotech firm SeekIn said on Thursday that it has received CE marking for its SeekInCare Cancer Detection Kit, a DNA-based blood test for early cancer detection.

CareDx reported after close of market on Thursday that its fourth quarter revenues increased 35 percent year over year, driven by testing services.

According to Radio Television Hong Kong and Sing Tao Daily reports on February 20, a study found that the new coronavirus may cause hypogonadism and decreased fertility in male patients, and patients will still be affected after recovery.

Cytiva cooperates with General Biology (Anhui) Co., Ltd. to build the world's first oligo FlexFactory. The investment scale of the production base reaches hundreds of millions of CNY.

Chinese diagnostic firm Amoy Diagnostics announced on Wednesday that it has entered into a collaboration agreement with French pharmaceutical firm Pierre Fabre to develop companion diagnostic kits in China.

Roche announced on Wednesday that it received CE marking for two of its SARS-CoV-2 tests to run on the firm's new Cobas 5800 system.

On February 21, the Notification on Regulating the Adjustment of Some Medical Service Prices, which included 16 assisted reproductive technologies such as artificial insemination and embryo transfer into Beijing medical insurance, was issued.